| __timestamp | Dyne Therapeutics, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 2613100000 |
| Thursday, January 1, 2015 | 2028000000 | 2891500000 |
| Friday, January 1, 2016 | 2281000000 | 3228800000 |
| Sunday, January 1, 2017 | 2932000000 | 2966700000 |
| Monday, January 1, 2018 | 24000 | 2900200000 |
| Tuesday, January 1, 2019 | 271000 | 3064100000 |
| Wednesday, January 1, 2020 | 700000 | 3248100000 |
| Friday, January 1, 2021 | 1088000 | 2722500000 |
| Saturday, January 1, 2022 | 3345000 | 2996200000 |
| Sunday, January 1, 2023 | 2461000 | 2975200000 |
Unleashing insights
In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost dynamics is crucial. Perrigo Company plc, a stalwart in the pharmaceutical industry, has consistently maintained a high cost of revenue, averaging around $3 billion annually from 2014 to 2023. This stability reflects its robust market presence and operational efficiency. In contrast, Dyne Therapeutics, Inc., a relatively newer player, showcases a more volatile trend. After peaking in 2017, Dyne's cost of revenue plummeted by over 99% in 2018, indicating a strategic pivot or operational restructuring. By 2023, Dyne's costs had stabilized, albeit at a significantly lower level than Perrigo's. This divergence highlights the contrasting strategies of established versus emerging companies in managing operational costs. As the industry continues to innovate, these trends offer valuable insights into the financial health and strategic directions of these companies.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Perrigo Company plc's Expenses
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Dyne Therapeutics, Inc.
Cost of Revenue Comparison: BioMarin Pharmaceutical Inc. vs Perrigo Company plc
BioMarin Pharmaceutical Inc. vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Perrigo Company plc's Expenses
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Perrigo Company plc
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Perrigo Company plc's Expenses
Comparing Cost of Revenue Efficiency: Alkermes plc vs Dyne Therapeutics, Inc.
Perrigo Company plc vs Vericel Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Vericel Corporation vs Dyne Therapeutics, Inc.
Iovance Biotherapeutics, Inc. vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored